Sharpening the teeth of EU social fundamental rights? The case of state pension age

This article analyzes current EU pension law and policy in light of the case “State Pension Age” (SPA) and considers the implications of this analysis for EU social rights. In examining the applicability of EU pension law, it provides two critical entry point of analysis into the SPA cases: i) Article 21 Charter Fundamental Rights of the European Union, and ii) The Internal Market scenario.publishedVersio

Sharpening the teeth of EU social fundamental rights? The case of state pension age

This article analyzes current EU pension law and policy in light of the case “State Pension Age” (SPA) and considers the implications of this analysis for EU social rights. In examining the applicability of EU pension law, it provides two critical entry point of analysis into the SPA cases: i) Article 21 Charter Fundamental Rights of the European Union, and ii) The Internal Market scenario.publishedVersio

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline

The purpose of this review article is to familiarize radiologists with the recently revised Response Evaluation Criteria in Solid Tumours (RECIST), used in many anticancer drug trials to assess response and progression rate. The most important modifications are: a reduction in the maximum number of target lesions from ten to five, with a maximum of two per organ, with a longest diameter of at least 10 mm; in lymph nodes (LNs) the short axis rather than the long axis should be measured, with normal LN measuring <10 mm, non-target LN ≥10 mm but <15 mm and target LN ≥15 mm; osteolytic lesions with a soft tissue component and cystic tumours may serve as target lesions; an additional requirement for progressive disease (PD) of target lesions is not only a ≥20% increase in the sum of the longest diameter (SLD) from the nadir but also a ≥5 mm absolute increase in the SLD (the other response categories of target lesion are unchanged); PD of non-target lesions can only be applied if the increase in non-target lesions is representative of change in overall tumour burden; detailed imaging guidelines. Alternative response criteria in patients with hepatocellular carcinoma and gastrointestinal stromal tumours are discussed

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: The CHARISMA randomized multicenter clinical trial

Background: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate de